Jonathan Koea1,2, Peter Baldwin3, Jessica Shen4, B Patel4, Jonathan Batiller4, Axel Arnaud4, James Hart4, Jeffrey Hammond4, Craig Fischer5, O James Garden6. 1. Department of Surgery, Auckland City Hospital, Grafton, New Zealand. jonathan.koea@waitematadhb.govt.nz. 2. Department of Surgery, North Shore Hospital, Private Bag 93505, Auckland, 0620, New Zealand. jonathan.koea@waitematadhb.govt.nz. 3. Addenbrooke's Hospital, Cambridge, UK. 4. Ethicon, Inc., Somerville, NJ, USA. 5. Weill Cornell Medical College of Cornell University, Houston, TX, USA. 6. Royal Infirmary of Edinburgh, Edinburgh, UK.
Abstract
BACKGROUND: In surgery, rapid hemostasis can be required in various settings and bleeding intensities to minimize complications related to blood loss. While effective hemostats are available for mild-to-moderate surgical bleeding, few are effective against challenging severe hemorrhage. We report the effectiveness and safety of the fibrin pad (FP), a novel combination hemostat (device/human biologic), in controlling severe soft-tissue bleeding as compared to the standard of care (SoC). METHODS: This randomized, controlled, superiority study enrolled subjects ≥18 years, requiring elective abdominal, retroperitoneal, pelvic, or thoracic (non-cardiac) surgery. A severe target bleeding site (TBS) was identified intra-operatively following which, subjects were randomized to the FP or the SoC group. Hemostatic status was observed at 4 min (primary endpoint) and 10 min post-randomization. Safety variables included TBS-related bleeding and thrombotic events. RESULTS: At 4 min post-randomization, 50/59 (84.7 %) subjects in the FP group and 10/32 (31.3%) [Corrected] subjects in the SoC group achieved hemostasis without needing re-treatment (P < 0.0001). Compared to the SoC group, the FP group showed better hemostasis at 10 min post-randomization [58/59 (98.3 %) vs. 28/32 (87.5 %); P = 0.01], lower mean time to hemostasis (6.1 ± 13.5 vs. 17.8 ± 32.0 min), and a less frequent need for re-treatment (5.1 vs. 53.1 %). The triangular test for binary response demonstrated the FP to be superior to SoC (95 % CI 1.474-3.290; P < 0.0001). Safety profiles in both groups were similar to those typically observed after long-duration surgery. CONCLUSION: The FP is safe and superior to SoC for controlling challenging severe soft-tissue bleeding encountered during intra-abdominal and thoracic surgical procedures.
RCT Entities:
BACKGROUND: In surgery, rapid hemostasis can be required in various settings and bleeding intensities to minimize complications related to blood loss. While effective hemostats are available for mild-to-moderate surgical bleeding, few are effective against challenging severe hemorrhage. We report the effectiveness and safety of the fibrin pad (FP), a novel combination hemostat (device/human biologic), in controlling severe soft-tissue bleeding as compared to the standard of care (SoC). METHODS: This randomized, controlled, superiority study enrolled subjects ≥18 years, requiring elective abdominal, retroperitoneal, pelvic, or thoracic (non-cardiac) surgery. A severe target bleeding site (TBS) was identified intra-operatively following which, subjects were randomized to the FP or the SoC group. Hemostatic status was observed at 4 min (primary endpoint) and 10 min post-randomization. Safety variables included TBS-related bleeding and thrombotic events. RESULTS: At 4 min post-randomization, 50/59 (84.7 %) subjects in the FP group and 10/32 (31.3%) [Corrected] subjects in the SoC group achieved hemostasis without needing re-treatment (P < 0.0001). Compared to the SoC group, the FP group showed better hemostasis at 10 min post-randomization [58/59 (98.3 %) vs. 28/32 (87.5 %); P = 0.01], lower mean time to hemostasis (6.1 ± 13.5 vs. 17.8 ± 32.0 min), and a less frequent need for re-treatment (5.1 vs. 53.1 %). The triangular test for binary response demonstrated the FP to be superior to SoC (95 % CI 1.474-3.290; P < 0.0001). Safety profiles in both groups were similar to those typically observed after long-duration surgery. CONCLUSION: The FP is safe and superior to SoC for controlling challenging severe soft-tissue bleeding encountered during intra-abdominal and thoracic surgical procedures.
Authors: Jonathan B Koea; Jonathan Batiller; Babahai Patel; Jessica Shen; Jeffrey Hammond; James Hart; Craig Fischer; O James Garden Journal: HPB (Oxford) Date: 2012-10-16 Impact factor: 3.647
Authors: Craig P Fischer; Christopher G Wood; Jessica Shen; Jonathan Batiller; James C Hart; Bababhai Patel; David M Albala Journal: Clin Appl Thromb Hemost Date: 2011-08-25 Impact factor: 2.389
Authors: Angel V Delgado; Bijan S Kheirabadi; Todd M Fruchterman; Michael Scherer; Douglas Cortez; Charles E Wade; Michael A Dubick; John B Holcomb Journal: J Trauma Date: 2008-01
Authors: Michael E Stokes; Xin Ye; Manan Shah; Katie Mercaldi; Matthew W Reynolds; Marcia F T Rupnow; Jeffrey Hammond Journal: BMC Health Serv Res Date: 2011-05-31 Impact factor: 2.655
Authors: Mitra Corral; Nicole Ferko; Andrew Hogan; Sarah S Hollmann; Gaurav Gangoli; Nadine Jamous; Jonathan Batiller; Richard Kocharian Journal: Clinicoecon Outcomes Res Date: 2016-09-21
Authors: Daniel J Del Gaizo; William D Spotnitz; Rachel W Hoffman; Mark Christopher Hermann; Linda S Sher; Russell H Spotnitz; Yuri S Genyk; Ian J Schorn; Daniel L Gillen; Bobby L White; Bruce G Miller; Roberto J Manson Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389